Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Current Press Releases

Keyword Search
 
Recent Press Releases | Archived Press Releases
DateTitle 
05/03/16Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PARSIPPANY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
05/02/16Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
-- Total Net Revenues Up 12 Percent Year-Over-Year -- -- EXPAREL® Net Revenues Up 14 Percent Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., May 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2016. “With immense leverage across our or... 
Printer Friendly Version
04/19/16Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer
PARSIPPANY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Charles A. Reinhart III to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently P... 
Printer Friendly Version
04/14/16Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., April 14, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-5... 
Printer Friendly Version
04/05/16Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
PARSIPPANY, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL® (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial O... 
Printer Friendly Version
03/08/16Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 08, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the co... 
Printer Friendly Version
03/01/16New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty
Data Presented at the Annual Meeting of the American Academy of Orthopaedic Surgeons PARSIPPANY, N.J., March 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of new data showing that EXPAREL® (bupivacaine liposome injectable suspension) infiltration compared to a standard analgesic regimen in patients undergoing total knee arthroplasty (TKA) significantly decreased the length of hospital stay and increased the likelihood that a patient would be d... 
Printer Friendly Version
02/25/16Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
-- 2015 Total Net Revenues Up 26 Percent Over 2014 -- -- 2015 EXPAREL® Net Revenues Up 27 Percent Over 2014 -- -- Per-Protocol Analysis of Oral Surgery Data Demonstrates Statistical Significance; Supports Launch Activities in Late Third Quarter 2016 --   -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain i... 
Printer Friendly Version
02/11/16Pacira Pharmaceuticals Announces Timing for 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2015 will be released before the market opens on Thursday, February 25, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, February 25, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-84... 
Printer Friendly Version
01/07/16Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million
PARSIPPANY, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015.  These estimates, which are unaudited, are based on management’s preliminary financial analysis. “We are pleased with the strong finish to 2015 and the preliminary revenues that benefited from a solid fourth quarter—seasonally the strongest period of the yea... 
Printer Friendly Version
12/28/15Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 4 p.m. PT (7 p.m. ET) on Monday, January 11, 2016, in San Francisco. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors &... 
Printer Friendly Version
12/15/15Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
-- Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Rescission of 2014 Warning Letter – -- Conference Call Today at 8:30 am EST – PARSIPPANY, N.J., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has achieved an amicable resolution with the United States in its lawsuit filed on September 8, 2015, Pacira Pharmaceuticals, Inc. et al v. United States Food &am... 
Printer Friendly Version
11/24/15Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET on Tuesday, December 1, in New York City. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
11/17/15New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
Pacira and HealthyWomen Launch ‘Voice Your Choice’ Campaign Urging Patients to Know and Discuss Their Pain Control Options Before Surgery PARSIPPANY, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- One in every 15 patients who receive prescription painkillers (also called opioids or narcotics) following surgery ends up using these medications long-term,1,2 which can result in tolerance, dependence and addiction. According to a new national survey, a lack of doctor-patient communication about postsurg... 
Printer Friendly Version
11/11/15Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
PARSIPPANY, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, president and chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies Autumn 2015 Global Healthcare Conference at 2:40 p.m. GMT (9:40 a.m. ET) on Thursday, November 19, in London. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Inve... 
Printer Friendly Version
11/06/15New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
Data Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons PARSIPPANY, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced positive data on the use of EXPAREL® (bupivacaine liposome injectable suspension) as a postsurgical analgesic following total knee replacement surgery. The study, which compared the use of EXPAREL infiltration to the standard of care in 1,110 patients, found that EXPAREL was associated with sign... 
Printer Friendly Version
10/27/15Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
-- Total Revenues of $62.2 Million in Third Quarter -- -- EXPAREL® Net Revenues of $59.7 Million in Third Quarter -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) --  Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2015. “Third quarter EXPAR... 
Printer Friendly Version
10/20/15Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
-- Dave Stack Remains Chairman and Chief Executive Officer; Continues to Drive Commercial Strategy and Clinical Development of EXPAREL® and the DepoFoam® Pipeline -- -- Mr. Scibetta to Lead Tactical Execution of Operations -- PARSIPPANY, N.J., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James S. Scibetta has been appointed president, effective October 20, 2015. In this capacity, Mr. Scibetta will oversee the day-to-day operations and ta... 
Printer Friendly Version
10/13/15Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (PCRX) today announced that financial results for the company’s third quarter ended September 30, 2015 will be released before the market opens on Tuesday, October 27, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, October 27, 2015, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1... 
Printer Friendly Version
09/08/15Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication
Complaint Challenges FDA’s Unlawful Efforts to Retroactively Restrict the Promotion of EXPAREL Despite Its Broad Indication PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today filed a lawsuit against the U.S. Food and Drug Administration (FDA) seeking to exercise its lawful rights to communicate truthful and non-misleading information about its flagship product, EXPAREL® (bupivacaine liposome ... 
Printer Friendly Version
08/19/15Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 19, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of James B. Jones, MD, PharmD, to the position of senior vice president and chief medical officer. Dr. Jones brings more than 25 years of experience as both a practicing and teaching physician and as a senior executive at biotechnology and pharmaceutical companies, where he led the clinical development of multiple novel pa... 
Printer Friendly Version
08/03/15Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 3, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the following investor conferences in August: Wedbush 2015 Life Sciences Management Access Conference at 8:00 a.m. ET in New York on Tuesday, August 11, 2015. ... 
Printer Friendly Version
07/30/15Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 30, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2015. “We recorded $57 million in EXPAREL product revenues in the second quarter, an increase o... 
Printer Friendly Version
07/15/15Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 15, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc. (NASDAQ: PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs. The randomized, blinded, multicenter pivotal study in dogs undergoing knee surger... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 30, 2015, at 9 a.m. ET. The call can be acc... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development. Dr. Braunstein brings over 20 years of knowledge and experience from his time both as a practicing physician and investor, as well as expertise from numerous commercial, consulting and operational roles advi... 
Printer Friendly Version
05/28/15Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 28, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it completed an End-of-Review process with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) for administration as a nerve block to provide postsurgical analgesia. Pacira requested an End-of-Review meeti... 
Printer Friendly Version
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com